(Nov.7.2018)

Daiichi Sankyo said on November 6 that the European Medicines Agency (EMA) has accepted a marketing approval application (MAA) for quizartinib for the treatment of adults with relapsed or refractory FLT3-ITD positive acute myeloid leukemia (AML). The regulators also granted accelerated assessment status to the agent ...

Jiho, Inc. is the sole copyright owner of all documents, images, and photographs on this website.
Any modification, reproduction, or use of any or all documents, images, and photographs on this website
by any unauthorized party is strictly prohibited.Copyright (C) JIHO,Inc.